ClinicalTrials.gg
Not yet recruitingNCT07125989AVE-BPCOUpdated Aug 15, 2025

Effect of Exercise Ventilatory Support Pressure on Endurance in Patients With Severe Chronic Obstructive Pulmonary Disease - AVE-BPCO

An interventional study of non-invasive ventilation in Chronic Obstructive Pulmonary Disease (COPD), sponsored by Centre Hospitalier Universitaire de Saint Etienne. Not yet recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-08-15.

Sponsored by Centre Hospitalier Universitaire de Saint Etienne · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 406 studies in Pulmonary Disease, Chronic Obstructive with a site in France — 71 open to participants now, 81 under way, 10 of them phase 3. Pulmonary Disease, Chronic Obstructive · France.

Planned enrollment
228th of 286
30 · median 138
Started
2025
with 18 others
No phase
158 of 406
37 open now
Primary completion
2027-01
later than 33 of 80 live
Registered
384th of 406
by date

Among the 406 studies in Pulmonary Disease, Chronic Obstructive with a site in France, this one is the 228th largest by planned enrollment of the 286 interventional ones that give a count, is one of 19 that started in 2025, is one of 158 with no phase, reaches primary completion later than 33 of the 80 other live ones, and was the 384th registered.

Pulmonary Disease, Chronic Obstructive

5,529 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 858 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

71 of the 406 studies in Pulmonary Disease, Chronic Obstructive with a site in France are open now. Recruiting first, the newest first:

66 more — sign in →

All 71 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 560 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 30 take children under 18; 88 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 406 studies in Pulmonary Disease, Chronic Obstructive with a site in France, or all of them as a file.
02

Study summary

Chronic obstructive pulmonary disease (COPD) is a chronic respiratory disease characterized by progressive obstruction of the airways. In advanced stages, it can progress to chronic respiratory failure with major respiratory repercussions.

Biologically, hyperinflation manifests as alveolar hypoventilation, which causes hypercapnia. Mechanically, it is responsible for an increase in ventilatory work associated with diaphragmatic muscle dysfunction and fatigue, leading to exercise incapacity.

Physical inactivity is a major predictor of mortality in patients with COPD. The recommendations of the European Respiratory Society (ERS) and the American Thoracic Society (ATS) emphasize the importance of exercise in the treatment and management of COPD.

Respiratory rehabilitation has been shown to have an indisputable effect on dyspnea and the quality of life of COPD patients. Current guidelines for respiratory rehabilitation recommend interventions at a frequency of at least 2 to 3 supervised high-intensity training sessions per week. A minimum of 4 weeks of physical training is necessary to achieve a significant improvement in quality of life, dyspnea, and endurance.

A reduction in the duration and intensity of sessions is often necessary, thus limiting the desired benefits of respiratory rehabilitation.

Non-invasive ventilation (NIV) provides mechanical respiratory assistance by helping inspiration and optimizing expiration through a non-invasive interface such as a mask. Its use during exercise in severe COPD is to try to correct hypercapnia, reduce dynamic hyperinflation by helping the respiratory muscles to improve their work, and reduce dyspnea and the feeling of muscle weakness.

However, the modalities in terms of ventilation mode and inspiratory support pressures are not clearly established.

Read the detailed description

The objective of this study is therefore to compare different levels of ventilatory assistance during exercise to determine whether the level of inspiratory assistance during exercise significantly improves endurance in these patients and, in particular, whether high-intensity ventilatory assistance (inspiratory assistance 21 +/- 3 cmH20) provides a greater benefit in terms of endurance time compared to moderate intensity (inspiratory assistance 13 +/- 3 cmH20) or low intensity (inspiratory assistance \< 6 cmH20).

03

Conditions studied

  • Chronic Obstructive Pulmonary Disease (COPD)

Keywords

  • Chronic obstructive pulmonary disease
  • respiratory rehabilitation
  • non-invasive ventilation
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • - stage GOLD III or IV
  • Baseline hypercapnia PaCO2 > 45 mmHg OR Alveolar hypoventilation during exercise (increase in PaCO2 > 5 mmHg),
  • Exhaustion of more than 80% of ventilatory reserve OR max power \< 50 Watts
  • Affiliation or entitlement to social security coverage
  • Signature of

Exclusion criteria

Exclusion Criteria:

  • > 35
  • Recent acute respiratory exacerbation \< 4 weeks
  • Severe unstable cardiac disease
  • Pneumothorax or pneumomediastinum
  • Pathological hypotension
  • Cerebrospinal fluid leak, recent head trauma, or cranial surgery
  • Severe bulbar disorder
  • Dehydration
  • Severe orthopedic or neurological disorder compromising rehabilitation.
  • Patient deprived of liberty or patient under guardianship
  • Pregnant woman
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Single (Participant)
Enrollment
30 participants (estimated)

Study arms

  • Sham comparator
    Low intensity

    Non-invasive ventilation less han 6 cmH2O

    Device: non-invasive ventilation

  • Active comparator
    Moderate intensity

    Non-invasive ventilation 13 +/-3 cmH2O

    Device: non-invasive ventilation

  • Experimental
    High intensity

    Non-invasive ventilation 21 +/-3 cmH2O

    Device: non-invasive ventilation

Interventions

  • Devicenon-invasive ventilation

    During the patient's first three respiratory rehabilitation sessions, each test on the cycle ergometer will be performed at 70% of maximum power (defined during the initial oxygen consumption (VO2) test) with ventilatory assistance at a different intensity (Low, moderate or high intensity).

06

What researchers measure

Primary outcomes

  1. Pedaling time limit (in seconds)

    Endurance capacity will be measured by the time limit for pedaling (in seconds) on a cycloergometer, performed during a respiratory rehabilitation session, at 70% of the maximum power developed during the maximum test.

    Time frame: Day 1, Day 3, Day 5

Secondary outcomes

  1. Partial pressure of oxygen (PaO2) in mmHg

    PaO2 measured by capillary blood gas analysis performed at peak exercise during a respiratory rehabilitation session

    Time frame: Day 1, Day 3, Day 5

  2. Partial pressure of carbon dioxide (PaCO2) in mmHg

    PaCO2 measured by capillary blood gas analysis performed at peak exercise during a respiratory rehabilitation session

    Time frame: Day 1, Day 3, Day 5

  3. Lactate in mmol/l

    Lactate measured by capillary blood gas analysis performed at peak exercise during a respiratory rehabilitation session

    Time frame: Day 1, Day 3, Day 5

  4. Peripheral muscle oxygenation (% SmO2)

    Measurement of peripheral muscle oxygenation (% SmO2) using near-infrared spectroscopy (NIRS) during exercise in an endurance test during a respiratory rehabilitation session.

    Time frame: Day 1, Day 3, Day 5

07

Study locations

1 site
  • CHU de Sint-Etienne
    Saint-Etienne, 42055, France
    • Frederic ROCHE, MD-PhD · Principal investigator
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Oct 2025; primary completion for Jan 2027, 15 months later.

Of 1,099 non-industry interventional studies with no phase under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's planned 15 months is below that.

Counting every sponsor, half of 1,187 studies reached it within 22 months; a quarter within 10 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 4, 2025
First posted
Aug 15, 2025
StartEst.
Oct 1, 2025
Primary completionEst.
Jan 2027
CompletionEst.
Jan 2027
Last update
Aug 15, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 15, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07125989
Responsible party
Sponsor
First posted
Aug 15, 2025
Start date
Oct 1, 2025 (estimated)
Primary completion
Jan 2027 (estimated)
Completion
Jan 2027 (estimated)
Last update
Aug 15, 2025

Study contacts

Frédéric ROCHE, MD-PhD
Contact
frederic.roche@univ-st-etienne.fr
+33(0)477829109
Frédéric ROCHE, MD-PhD
principal investigator · CHU de Saint-Etienne

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion